// App-Quantinova.ai

: Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Researchers

Presenter

  • Sebastian Grosicki

Principal Investigators

  • Ulf-Henrik Mellqvist

  • Łukasz Pruchniewski

  • Jacob Crafoord

  • Suzanne Trudel

  • Chang-Ki Min

  • Darrell White

  • Adrian Alegre

  • Markus Hansson

  • Takashi Ikeda

  • Kazutaka Sunami

  • Eric Leip

  • Arthur Kudla

  • Gregory Finn

  • Youngil Koh

Medical Centers

  • Centrum Medyczne Pratia Poznań, Poznań, Poland

  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)

  • Department of Hematology, South Elfsborg Hospital, Borås, Sweden

  • Department of Hematology and Cancer Prevention, Medical University of Silesia, Katowice, Poland

  • Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)

  • Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan

  • Division of Hematology, Princess Margaret Cancer Center, Toronto, Canada

  • Division of Hematology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Canada

  • Department of Hematology, Sahlgrenska University Hospital, Göteborg, Sweden

  • Department of Hematology, Örebro University Hospital, Örebro, Sweden

  • Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan

  • Department of Hematology, Univeritary Hospital La Princesa, Madrid, Spain

Locations

  • Poland

  • Sweden

  • Canada

  • Turkmenistan

  • United States

  • Republic of South Korea

  • Japan

  • Spain

Companies

  • PharmAbcine Inc.

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Multiple Myeloma

  • Cytokine release syndrome

Biomarkers

  • Twist-related protein 1

Drug/Treatment

  • Lenalidomide

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • Safety

  • Multinational

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved